The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.
Horizon Therapeutics announced the availability of Procysbi (cysteamine bitartrate) delayed-release oral granules in tear-open packets for the treatment of nephropathic cystinosis in patients aged 1 year and older.
But high average blood pressure on 24-hour test strongly predicts child’s cardiac, kidney disease risk.
Survival up from 1970-1985 to 2005-2015 mainly due to drop in deaths from CV causes, infections.
The FDA has approved Procysbi (cysteamine bitartrate; Horizon Therapeutics) delayed-release oral granules, a new formulation for the treatment of nephropathic cystinosis in patients aged 1 year and older.
A recent systematic review identified several established as well as emerging practices utilized in the pediatric setting that were associated with overuse of medical care.
Potentially nephrotoxic meds prescribed at higher rate to children with versus without chronic kidney disease.
Rates of early-onset CVD higher for offspring of mothers with history of CVD, diabetes complications.
Higher risk for ESKD, death suggests closer monitoring needed, especially in first year after surgery
The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients aged 1 month and older.
